VivoSeq
Cardiovascular

Pulmonary Arterial Hypertension

157

Pipeline Programs↗

42

Active Trials↗

52

Companies Involved↗

Pulmonary Arterial Hypertension is a highly competitive landscape with 157 programs across 52 companies. The most active players are Menarini International Operations Luxembourg SA, BioMarin Pharmaceutical, Mirati Therapeutics Inc.. 43 therapies are approved with 25 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

41/100

Mech. Concentration

7/100

Completion Rate

70/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Menarini International Operations Luxembourg SA

1 program

Phase 1BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

1 program

Phase 1M

Mirati Therapeutics Inc.

1 program

Phase 1K

Keros Therapeutics, Inc.

4 programs

Phase 2Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.

2 programs

Phase 2E

Eiger BioPharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical13

Hyperpolarized 13c Pyruvate

University of Maryland, Baltimore

Diltiazem Hydrochloride

University of South Florida

Hyperpolarized Xe129

University of Kansas Medical Center

Assigned Pulmonary Hypertension Medication

Bayer

PAH Medication

Bayer

Phase 118

Ranolazine

Menarini International Operations Luxembourg SA

Anakinra

Swedish Orphan Biovitrum

Sapropterin Dihydrochloride

BioMarin Pharmaceutical

Sulfasalazine

Pfizer

Sorafenib

Bayer

Phase 258

Morphine Sulfate

Merck & Co.

Pioglitazone

Takeda

Sodium Nitrite

Hope Pharmaceuticals

Nilotinib

Azurity Pharmaceuticals

Trimetazidine

IRCCS San Raffaele

Phase 325

Ipratropium Bromide

Boehringer Ingelheim

Iloprost

BTG International Inc.

Bardoxolone Methyl

Biogen

Udenafil

Mezzion Pharma Co. Ltd

Imatinib

Novartis

Approved43

Bosentan

Johnson & Johnson

Epinephrine

Samson Clinical Operations Pty Ltd

Nitric Oxide

Mallinckrodt

Nitroglycerin

Viatris Specialty LLC

Riociguat

Bayer

Analysis

Modality Breakdown

96%

Small molecule

162 of 169 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody32%Protein / enzyme32%Cell therapy1<1%

Small molecule leads; the ring shows all 169 classified programs, each share of the total. Modality classified for 98% of 180 pipeline programs.

Analysis

Trial Status

282

clinical trials

Completed154 · 55%
Terminated45 · 16%
Withdrawn21 · 7%
Unknown status17 · 6%
Active, not recruiting15 · 5%
Recruiting15 · 5%
Other15 · 5%

Clinical Trials

Trial Activity

282 trials

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT05587712·42 enrolled
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
Recruiting·CChina National Center for Cardiovascular Diseases·Phase 1·NCT06554301·72 enrolled
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
Recruiting·UUniversity of Minnesota·Phase 1·NCT06481852·24 enrolled
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
Recruiting·AAllRock Bio, Inc.·Phase 2·NCT07175038·40 enrolled
Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension
Recruiting·National Medical Research Center for Cardiology, Ministry of Health of Russian Federation·Phase 2/3·NCT06683040·260 enrolled
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
Recruiting·AAmsterdam UMC, location VUmc·Phase 4·NCT06658522·20 enrolled
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Recruiting·—·Phase 1·NCT06872112·15 enrolled
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
Recruiting·—·Phase 4·NCT07356778·36 enrolled
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Recruiting·—·Phase 2·NCT06104228·20 enrolled
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
Recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT04972656·420 enrolled
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Recruiting·Pfizer logoPfizer·Phase 2·NCT07073820·36 enrolled
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07218029·815 enrolled
A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Recruiting·National Institutes of Health Clinical Center (CC)·Phase 2·NCT01712620·70 enrolled
ACTION - The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
Recruiting·UUniversity of Sao Paulo General Hospital·N/A·NCT07013149·183 enrolled
VOYAGER-PAH: Sotatercept Long-Term Extension
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT04811092·600 enrolled
Page 1 of 19

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)